We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
Teacher Retirement System of Texas
176
Teacher Retirement System of Texas
Texas
– -$3.39M -25,732 Closed
Zurich Cantonal Bank
177
Zurich Cantonal Bank
Switzerland
– -$3.31M -25,079 Closed
VAM
178
Vazirani Asset Management
New York
– -$3.3M -25,000 Closed
GCM
179
Greenland Capital Management
New York
– -$3.2M -24,224 Closed
EGM
180
Engineers Gate Manager
New York
– -$3.17M -24,032 Closed
SEI Investments
181
SEI Investments
Pennsylvania
– -$3.12M -23,637 Closed
EAM
182
Erste Asset Management
Austria
– -$3.08M -23,400 Closed
Canada Life
183
Canada Life
Manitoba, Canada
– -$3.06M -23,168 Closed
CC
184
Carlson Capital
Texas
– -$3.03M -23,000 Closed
CM
185
Capula Management
Cayman Islands
– -$3.01M -22,800 Closed
PC
186
Paulson & Co
New York
– -$2.84M -21,500 Closed
CUAMC
187
China Universal Asset Management Company
China
– -$2.81M -21,328 Closed
GC
188
Guggenheim Capital
Illinois
– -$2.8M -21,241 Closed
Cerity Partners
189
Cerity Partners
New York
– -$2.7M -20,446 Closed
BCA
190
Burren Capital Advisors
Gibraltar
– -$2.65M -20,074 Closed
DTL
191
Dynamic Technology Lab
Singapore
– -$2.58M -19,560 Closed
Creative Planning
192
Creative Planning
Kansas
– -$2.55M -19,322 Closed
ECM
193
ExodusPoint Capital Management
New York
– -$2.49M -18,843 Closed
GAM
194
Gotham Asset Management
New York
– -$2.44M -18,508 Closed
Stifel Financial
195
Stifel Financial
Missouri
– -$2.43M -18,447 Closed
LIP
196
Lighthouse Investment Partners
Florida
– -$2.33M -17,666 Closed
Carson Wealth (CWM LLC)
197
Carson Wealth (CWM LLC)
Nebraska
– -$2.22M -16,812 Closed
AAI
198
Aequim Alternative Investments
California
– -$1.98M -15,000 Closed
BPAMU
199
BTG Pactual Asset Management US
New York
– -$1.98M -15,000 Closed
Nomura Holdings
200
Nomura Holdings
Japan
– -$1.89M -14,313 Closed
6 7
8
9 10

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.